Search research articles
Contact Us
Filters
Showing results (161-170 of 224) with videos related to
Page
of 23
Sort By:
Seminars in Oncology Nursing
|
May 24, 2025
Acceptability of an Electronic Patient-Reported Outcomes-Based Model of Care to Monitor Symptoms Related to Cancer Treatment with Immune Checkpoint Inhibitors: Results from the IePRO Randomized Controlled Trial
André Manuel da Silva Lopes, Stellio Giacomini, Ambily Ulahannan, et al.
Clinical Lung Cancer
|
August 8, 2025
Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen
Andrea Riccardo Filippi, Eliana Rulli, Diego Signorelli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 31, 2022
Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials
Giuseppe Luigi Banna, Alessio Signori, Alessandra Curioni-Fontecedro, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 5, 2008
Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Diego Dongiovanni, Lorenzo Daniele, Carla Barone, et al.
Trials
|
August 31, 2018
Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial
Duneesha de Fonseka, Anna Morley, Louise Stadon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 7, 2024
Lung Cancer in Switzerland
Raphael Sven Werner, Alessandra Curioni-Fontecedro, Laetitia A Mauti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2024
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Michael Mark, Patrizia Froesch, Katrin Gysel, et al.
Translational Lung Cancer Research
|
July 14, 2022
Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trial
Yanjun Xu, Zhiyu Huang, Jian Fang, et al.
Journal of Thoracic Disease
|
May 20, 2021
High expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastases
Lu Dai, Yi-Hua Li, Ying-Ying Liang, et al.
Translational Lung Cancer Research
|
March 4, 2022
Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study
Huiping Qiang, Yuqiong Lei, Yinchen Shen, et al.
Page
of 23
Search research articles
Search
Showing results (161-170 of 224) with videos related to
Sort By:
Page
of 23
Seminars in Oncology Nursing
|
May 24, 2025
Acceptability of an Electronic Patient-Reported Outcomes-Based Model of Care to Monitor Symptoms Related to Cancer Treatment with Immune Checkpoint Inhibitors: Results from the IePRO Randomized Controlled Trial
André Manuel da Silva Lopes, Stellio Giacomini, Ambily Ulahannan, et al.
Clinical Lung Cancer
|
August 8, 2025
Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen
Andrea Riccardo Filippi, Eliana Rulli, Diego Signorelli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 31, 2022
Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials
Giuseppe Luigi Banna, Alessio Signori, Alessandra Curioni-Fontecedro, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 5, 2008
Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Diego Dongiovanni, Lorenzo Daniele, Carla Barone, et al.
Trials
|
August 31, 2018
Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial
Duneesha de Fonseka, Anna Morley, Louise Stadon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 7, 2024
Lung Cancer in Switzerland
Raphael Sven Werner, Alessandra Curioni-Fontecedro, Laetitia A Mauti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2024
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Michael Mark, Patrizia Froesch, Katrin Gysel, et al.
Translational Lung Cancer Research
|
July 14, 2022
Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trial
Yanjun Xu, Zhiyu Huang, Jian Fang, et al.
Journal of Thoracic Disease
|
May 20, 2021
High expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastases
Lu Dai, Yi-Hua Li, Ying-Ying Liang, et al.
Translational Lung Cancer Research
|
March 4, 2022
Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study
Huiping Qiang, Yuqiong Lei, Yinchen Shen, et al.
Page
of 23